temozolomide has been researched along with Hypoxia in 18 studies
Hypoxia: Sub-optimal OXYGEN levels in the ambient air of living organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)." | 8.12 | Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022) |
| "This study explored the effects of telomerase reverse transcriptase (TERT) promoter mutations on transcriptional activity of the TERT gene under hypoxic and temozolomide (TMZ) treatment conditions, and investigated the status and prognostic value of these mutations in gliomas." | 7.80 | TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. ( Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X, 2014) |
| " In contrast, the cytotoxic drug temozolomide, when used in combination with HIF-1alpha knockdown, exhibited a superadditive and likely synergistic therapeutic effect compared with the monotherapy of either treatment alone in the D54MG glioma model." | 5.33 | Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. ( Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR, 2006) |
| "This study aims to investigate the role of hypoxia-induced long non-coding small nucleolar RNA host gene 14 (lncRNA SNHG14) in glioma temozolomide (TMZ) resistance and underlying mechanisms." | 4.12 | Mechanisms for hypoxia ( Gong, M; Liao, X; Liao, Y; Liu, Y; Meng, L; Mo, X; Zhao, H, 2022) |
| "Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)." | 4.12 | Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022) |
| "This study explored the effects of telomerase reverse transcriptase (TERT) promoter mutations on transcriptional activity of the TERT gene under hypoxic and temozolomide (TMZ) treatment conditions, and investigated the status and prognostic value of these mutations in gliomas." | 3.80 | TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. ( Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X, 2014) |
| " This drug combination significantly impaired the sphere-forming ability of GSCs in vitro and tumor formation in vivo, leading to increase in the overall survival of mice bearing orthotopic inoculation of GSCs." | 1.39 | Effective elimination of cancer stem cells by a novel drug combination strategy. ( Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H, 2013) |
| " In contrast, the cytotoxic drug temozolomide, when used in combination with HIF-1alpha knockdown, exhibited a superadditive and likely synergistic therapeutic effect compared with the monotherapy of either treatment alone in the D54MG glioma model." | 1.33 | Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. ( Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 12 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Torres, JP | 1 |
| Lin, Z | 1 |
| Fenton, DS | 1 |
| Leavitt, LU | 1 |
| Niu, C | 1 |
| Lam, PY | 1 |
| Robes, JM | 1 |
| Peterson, RT | 1 |
| Concepcion, GP | 1 |
| Haygood, MG | 1 |
| Olivera, BM | 1 |
| Schmidt, EW | 1 |
| Zhao, H | 1 |
| Meng, L | 2 |
| Liao, X | 1 |
| Liu, Y | 1 |
| Mo, X | 1 |
| Gong, M | 1 |
| Liao, Y | 2 |
| Zhang, G | 1 |
| Tao, X | 1 |
| Ji, B | 1 |
| Gong, J | 1 |
| Su, X | 1 |
| Xie, Y | 2 |
| Zhang, J | 2 |
| Li, M | 1 |
| Zhang, Q | 1 |
| Jin, G | 1 |
| Liu, F | 1 |
| Wu, P | 1 |
| Guo, J | 1 |
| Yang, H | 1 |
| Yuan, D | 1 |
| Wang, C | 1 |
| Wang, Z | 2 |
| Lu, X | 1 |
| Liu, M | 1 |
| Liu, L | 1 |
| Wang, R | 1 |
| Yang, K | 1 |
| Xiao, H | 1 |
| Li, J | 2 |
| Tang, X | 1 |
| Liu, H | 1 |
| Li, T | 1 |
| Fu, X | 1 |
| Wang, J | 2 |
| Shang, W | 1 |
| Wang, X | 2 |
| Zhang, L | 2 |
| Lickliter, JD | 1 |
| Ruben, J | 1 |
| Kichenadasse, G | 1 |
| Jennens, R | 1 |
| Gzell, C | 1 |
| Mason, RP | 1 |
| Zhou, H | 1 |
| Becker, J | 1 |
| Unger, E | 1 |
| Stea, B | 1 |
| Liu, J | 1 |
| Gao, L | 1 |
| Zhan, N | 1 |
| Xu, P | 1 |
| Yang, J | 1 |
| Yuan, F | 1 |
| Xu, Y | 1 |
| Cai, Q | 1 |
| Geng, R | 1 |
| Chen, Q | 1 |
| Yin, J | 1 |
| Ge, X | 2 |
| Shi, Z | 2 |
| Yu, C | 1 |
| Lu, C | 1 |
| Wei, Y | 1 |
| Zeng, A | 1 |
| Yan, W | 1 |
| You, Y | 1 |
| Cheng, HS | 1 |
| Marvalim, C | 1 |
| Zhu, P | 1 |
| Law, CLD | 1 |
| Low, ZYJ | 1 |
| Chong, YK | 1 |
| Ang, BT | 1 |
| Tang, C | 1 |
| Tan, NS | 1 |
| Chen, JC | 1 |
| Hwang, JH | 1 |
| Bielecka-Wajdman, AM | 1 |
| Lesiak, M | 1 |
| Ludyga, T | 1 |
| Sieroń, A | 1 |
| Obuchowicz, E | 1 |
| Pan, MH | 1 |
| Wang, L | 2 |
| Li, W | 1 |
| Jiang, C | 1 |
| He, J | 1 |
| Abouzid, K | 1 |
| Liu, LZ | 1 |
| Jiang, BH | 1 |
| Wei, M | 1 |
| Ma, R | 1 |
| Huang, S | 1 |
| Ding, Y | 1 |
| Li, Z | 2 |
| Guo, Q | 1 |
| Tan, R | 1 |
| Zhao, L | 1 |
| Chen, C | 1 |
| Han, S | 1 |
| Zhang, X | 1 |
| Wu, A | 1 |
| Yuan, S | 1 |
| Wang, F | 1 |
| Chen, G | 1 |
| Zhang, H | 1 |
| Feng, L | 1 |
| Colman, H | 1 |
| Keating, MJ | 1 |
| Li, X | 1 |
| Xu, RH | 1 |
| Huang, P | 1 |
| Li, L | 1 |
| Lin, X | 1 |
| Shoemaker, AR | 1 |
| Albert, DH | 1 |
| Fesik, SW | 1 |
| Shen, Y | 1 |
18 other studies available for temozolomide and Hypoxia
| Article | Year |
|---|---|
Boholamide A, an APD-Class, Hypoxia-Selective Cyclodepsipeptide.
Topics: Antineoplastic Agents; Biological Products; Calcium; Cytotoxins; Depsipeptides; Hypoxia; Molecular S | 2020 |
Mechanisms for hypoxia
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Hypoxia; | 2022 |
Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Endothelial Cells; Glioblastoma; Humans; Hypoxia; Macrophages; Ph | 2022 |
HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Ferr | 2022 |
Exosomes Derived from Hypoxic Glioma Cells Reduce the Sensitivity of Glioma Cells to Temozolomide Through Carrying miR-106a-5p.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopla | 2022 |
A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; DNA; Drug Resistanc | 2022 |
Mechanism of NURP1 in temozolomide resistance in hypoxia-treated glioma cells via the KDM3A/TFEB axis.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Disease Models, Ani | 2023 |
Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme.
Topics: Emulsions; Glioblastoma; Humans; Hypoxia; Oxygen; Radiation-Sensitizing Agents; Temozolomide | 2023 |
Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Biomarkers, Tumor; Cell Movemen | 2020 |
Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Prol | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Topics: Animals; Antagomirs; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-A | 2018 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aryl Hydrocarbon Rece | 2006 |